GlaxoSmithKline Asthma Treatment Gets Green Light From EC for Self Administering
01 Agosto 2019 - 10:11AM
Noticias Dow Jones
By Oliver Griffin
GlaxoSmithKline PLC (GSK.LN) on Thursday said two new methods
for self-administering its Nucala treatment for severe eosinophilic
asthma has received marketing authorization from the European
Commission.
The pharmaceutical company said the EC has authorized marketing
for a prefilled pen and a prefilled safety syringe that people
suffering with severe eosinophilic asthma can take at home, once a
health-care professional has decided the treatment is
appropriate.
Write to Oliver Griffin at oliver.griffin@dowjones.com;
@OliGGriffin
(END) Dow Jones Newswires
August 01, 2019 10:56 ET (14:56 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024